Branded Legacy Advances Engineering of Air-Driven Intranasal Drug Delivery Platform

Branded Legacy, Inc. (OTC: BLEG) has announced that its subsidiary, BioLegacy Evaluative Group Inc., has initiated engineering and development of a unitary device mold for its proprietary air-driven intranasal drug delivery platform. This development represents a significant manufacturing milestone that advances scalable production capabilities for the company's single-use device designed for rapid and reliable therapeutic delivery.

The engineering progress specifically supports Branded Legacy's flagship inhaled naloxone program, positioning the company to address critical needs in opioid overdose reversal. This advancement builds upon the company's September 2025 provisional patent filing and complements the recent opening of a GMP-compliant facility in Vancouver. The combination of intellectual property protection and manufacturing infrastructure strengthens the company's capacity to deliver affordable, high-quality pharmaceutical solutions to combat the ongoing opioid crisis.

The air-driven intranasal delivery platform represents an innovative approach to medication administration that could potentially improve treatment accessibility and effectiveness. By focusing on scalable production through unitary device mold engineering, Branded Legacy aims to ensure consistent quality and reliable performance across manufactured units. This development phase is crucial for transitioning from prototype to mass production, enabling broader distribution of potentially life-saving treatments.

Branded Legacy maintains strategic collaborations with leading academic institutions including McMaster University and Stanford University, leveraging these partnerships to drive transformative research and innovation in addiction treatment and harm reduction. The company's comprehensive approach combines research excellence with manufacturing capability, positioning it as a significant contributor to addressing public health challenges. More information about the company's initiatives can be found at https://BrandedLegacy.com.

The implications of this engineering advancement extend beyond technical manufacturing progress. As the opioid crisis continues to affect communities worldwide, improved delivery systems for reversal medications like naloxone could enhance emergency response capabilities and save lives. The development of reliable, single-use devices supports harm reduction strategies by making critical interventions more accessible to first responders, healthcare providers, and at-risk individuals. This manufacturing milestone represents an important step toward making innovative addiction treatment solutions more widely available to those who need them most.